Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos N Papandreou

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Nutrition and Cancer|November 22, 2011
Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosisIoannis Gioulbasanis, Anna Patrikidou, Kyriaki Kitikidou, et al.
BMC Cancer|September 16, 2010
Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinomaKonstantinos T Papazisis, Lukas F Kontovinis, Christos N Papandreou, et al.
Cancer|January 28, 2003
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinomaDanai D Daliani, Vasily Assikis, Shi-Ming Tu, et al.
BJU International|April 3, 2009
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinomaDanai D Daliani, Nizar M Tannir, Christos N Papandreou, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 14, 2012
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cellsKonstantinos Tsapakidis, Panagiotis J Vlachostergios, Ioannis A Voutsadakis, et al.
Pathology Oncology Research : POR|July 26, 2011
p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancerPanagiotis J Vlachostergios, Foteini Karasavvidou, Anna Patrikidou, et al.
Urologic Oncology|December 13, 2003
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)Shi-Ming Tu, Randall E Millikan, Lance C Pagliaro, et al.
Prostate Cancer|June 6, 2012
Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomyPanagiotis J Vlachostergios, Foteini Karasavvidou, Grigorios Kakkas, et al.
Clinical Breast Cancer|April 8, 2014
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancerGeorge Pentheroudakis, Vassiliki Kotoula, George Kouvatseas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potentialVasily J Assikis, Kim-Anh Do, Sijin Wen, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Nutrition and Cancer|November 22, 2011
Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosisIoannis Gioulbasanis, Anna Patrikidou, Kyriaki Kitikidou, et al.
BMC Cancer|September 16, 2010
Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinomaKonstantinos T Papazisis, Lukas F Kontovinis, Christos N Papandreou, et al.
Cancer|January 28, 2003
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinomaDanai D Daliani, Vasily Assikis, Shi-Ming Tu, et al.
BJU International|April 3, 2009
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinomaDanai D Daliani, Nizar M Tannir, Christos N Papandreou, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 14, 2012
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cellsKonstantinos Tsapakidis, Panagiotis J Vlachostergios, Ioannis A Voutsadakis, et al.
Pathology Oncology Research : POR|July 26, 2011
p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancerPanagiotis J Vlachostergios, Foteini Karasavvidou, Anna Patrikidou, et al.
Urologic Oncology|December 13, 2003
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)Shi-Ming Tu, Randall E Millikan, Lance C Pagliaro, et al.
Prostate Cancer|June 6, 2012
Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomyPanagiotis J Vlachostergios, Foteini Karasavvidou, Grigorios Kakkas, et al.
Clinical Breast Cancer|April 8, 2014
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancerGeorge Pentheroudakis, Vassiliki Kotoula, George Kouvatseas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potentialVasily J Assikis, Kim-Anh Do, Sijin Wen, et al.
Pageof 6